Francesco Carubbi

Dr. Francesco Carubbi

Internal Medicine and Nephrology Unit, Department of Life, Health and Environmental Sciences, Department of Medicine, University of L'Aquila, ASL 1 Avezzano-Sulmona-L'Aquila, L'Aquila, Italy.
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
FCFrancesco Carubbi
Francesco Carubbi
PCPaola Cipriani
Paola Cipriani
AMAlessandra Marrelli
Alessandra Marrelli
PBPaola Di Benedetto
Paola Di Benedetto
PRPiero Ruscitti
Piero Ruscitti
RGRoberto Giacomelli
Roberto Giacomelli
Introduction: Primary Sjögren’s syndrome (pSS) is an autoimmune disorder affecting exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular involvement leading to a worsening of disease prognosis. Current therapeutic options are mainly empiric and often translated by other autoimmune diseases. In the last few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS. Patients with early active disease appear to be those who could benefit the most from RTX. The aim of this study was to investigate the efficacy and safety of RTX in comparison to disease modifying anti-rheumatic drugs (DMARDs) in early active pSS patients. Methods: Forty-one patients with early pSS and active disease (EULAR Sjogren’s syndrome disease activity index, ESSDAI ≥ 6) were enrolled in the study. Patients were treated with either RTX or DMARDs in two different Rheumatology centers and followed up for 120 weeks. Clinical assessment was performed by ESSDAI every 12 weeks up to week 120 and by self-reported global disease activity pain, sicca symptoms and fatigue on visual analogic scales, unstimulated saliva flow and Schirmer’s I test at week 12, 24, 48, 72, 96, and 120. Laboratory assessment was performed every 12 weeks to week 120. Two labial minor salivary gland (MSG) biopsies were obtained from all patients at the time of inclusion in the study and at week 120. Results: Our study demonstrated that RTX treatment results in a faster and more pronounced decrease of ESSDAI and other clinical parameters compared to DMARDs treatment. No adverse events were reported in the two groups. We also observed that RTX is able to reduce glandular infiltrate, interfere with B/T compartmentalization and consequently with the formation of ectopic lymphoid structures and germinal center-like structures in pSS-MSGs. Conclusions: To our knowledge, this is the first study performed in a large cohort of early active pSS patients for a period of 120 weeks. We showed that RTX is a safe and effective agent to be employed in pSS patients with systemic, extra-glandular involvement. Furthermore, our data on pSS-MSGs provide additional biological basis to employ RTX in this disease.

28 November 2017 in BMC Rheumatology
Verified
Journal Article
Open access
PDF file
Alessia AlunnoAlessia Alunno
Alessia Alunno
FCFrancesco Carubbi
Francesco Carubbi
RGRoberto Giacomelli
Roberto Giacomelli
RGRoberto Gerli
Roberto Gerli
In recent years, the landscape of pro- and anti-inflammatory cytokines has rapidly expanded with the identification of new members proven to be involved at different extent in the pathogenesis of chronic immune mediated inflammatory diseases including rheumatoid arthritis (RA). The advance of our understanding of mediators involved in the pathogenesis of RA and in consequence, the development of novel targeted therapies is necessary to provide patients not responding to currently available strategies with novel compounds. The aim of this review article is to provide an overview on recently identified cytokines, emphasizing their pathogenic role and therapeutic potential in RA. A systematic literature review was performed to retrieve articles related to every cytokine discussed in the review. In some cases, evidence from animal models and RA patients is already consistent to move forward into drug development. In others, conflicting observation and the paucity of data require further investigations.Forty years after the discovery of IL-1, the landscape of cytokines is continuously expanding with increasing possibilities to develop novel therapeutic strategies in RA.

1 January 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
BBBianca Bech
Bianca Bech
JPJette Primdahl
Jette Primdahl
ATAstrid van Tubergen
Astrid van Tubergen
MVMarieke Voshaar
Marieke Voshaar
HZHeidi A Zangi
Heidi A Zangi
YEYvonne van Eijk-Hustings
Yvonne van Eijk-Hustings

1 March 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FCFrancesco Carubbi
Francesco Carubbi
LSLia Salvati
Lia Salvati
AAAlessia Alunno
Alessia Alunno
FMFabio Maggi
Fabio Maggi
EBErika Borghi
Erika Borghi
DGDavide Grassi
Davide Grassi
The coronavirus 2019 disease (COVID-19) is characterised by a heterogeneous clinical presentation, a complex pathophysiology and a wide range of imaging findings, depending on disease severity and time course. We conducted a retrospective evaluation of hospitalized patients with proven SARS-CoV-2 infection, clinical signs of COVID-19 and computed tomography (CT) scan-proven pulmonary involvement, in order to identify relationships between clinical, serological, imaging data and disease outcomes in patients with COVID-19. Clinical and serological records of patients admitted to two COVID-19 Units of the Abruzzo region in Italy with proven SARS-CoV-2 pulmonary involvement investigated with CT scan, assessed at the time of admission to the hospital, were retrospectively evaluated. Sixty-one patients (22 females and 39 males) of median age 65 years were enrolled. Fifty-six patients were discharged while death occurred in 5 patients. None of the lung abnormalities detected by CT was different between discharged and deceased patients. No differences were observed in the features and extent of pulmonary involvement according to age and gender. Logistic regression analysis with age and gender as covariates demonstrated that ferritin levels over the 25th percentile were associated with the involvement of all 5 pulmonary lobes (OR = 14.5, 95% CI 2.3–90.9, p = 0.004), the presence of septal thickening (OR = 8.2, 95% CI 1.6–40.9, p = 0.011) and the presence of mediastinal lymph node enlargement (OR = 12.0, 95% CI 1.1–127.5, p = 0.039) independently of age and gender. We demonstrated that ferritin levels over the 25th percentile are associated with a more severe pulmonary involvement, independently of age and gender and not associated with disease outcomes. The identification of reliable biomarkers in patients with COVID-19 may help guiding clinical decision, tailoring therapeutic approaches and ultimately improving the care and prognosis of patients with this disease.

13 April 2018 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
AAAlessia Alunno
Alessia Alunno
MLMaria Comasia Leone
Maria Comasia Leone
RGRoberto Giacomelli
Roberto Giacomelli
RGRoberto Gerli
Roberto Gerli
FCFrancesco Carubbi
Francesco Carubbi
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease mainly affecting exocrine glands and leading to impaired secretory function. The clinical picture is dominated by signs and symptoms of mucosal dryness and the course of the disease is mild and indolent in the majority of cases. However, a subgroup of patients can also experience extraglandular manifestations that worsen the disease prognosis. pSS patients are consistently found to have a higher risk of developing non-Hodgkin lymphoma (NHL) compared with patients with other autimmune disorders and to the general population. NHL is the most severe comorbidity that can occur in pSS, therefore recent research has aimed to identify reliable clinical, serological, and histological biomarkers able to predict NHL development in these subjects. This review article encompasses the body of evidence published so far in this field highlighting the challenges and pitfalls of different biomarkers within clinical practice. We also provide an overview of epidemiological data, diagnostic procedures, and evidence-based treatment strategies for NHL in pSS.

1 June 2014 in Journal of Autoimmunity
Verified
Journal Article
Closed access
AAAlessia Alunno
Alessia Alunno
FCFrancesco Carubbi
Francesco Carubbi
OBOnelia Bistoni
Onelia Bistoni
SCSara Caterbi
Sara Caterbi
RGRoberto Gerli
Roberto Gerli
RGRoberto Gerli
Roberto Gerli